CSChadi Saad

Chadi Saad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chadi Saad has a total of 258 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mapping the path to clinical implementation of multi-omics

    by Said I. Ismail, Chadi Saad, Mohamed A. Elrayess, Ahmad A. L. Khleifat, Nagham Nafiz Hendi, Yasser AlSarraj, Radja Messai Badji, Wadha A. A. L. Muftah

    Multi-omics promises to transform medicine by providing holistic disease insights through interacting molecular layers, involving DNA, RNA, proteins and metabolites. The underlying technologies have matured rapidly, currently enabling higher throughputs at lower costs. Yet as multi-omics moves from research to routine care, the central challenge is no longer data generation, but standardizing and interpreting complexity within health systems built for discrete tests. In this Perspective, we chart the path from assay to implementation by demonstrating how integrative analyses outperform single modalities, as well as by emphasizing that multiplexing, high dimensionality and probabilistic interpretation introduce risks to reproducibility and clinical validity. We examine computational strategies for multimodal integration, highlighting the importance of explainable AI for auditability and regulatory trust. Drawing on lessons from early national programs, we suggest that scalable clinical adoption depends on interoperable digital infrastructures, harmonized quality standards and multidisciplinary care models that embed multi-omics into everyday practice.


  • Caractérisation des erreurs de séquençage non aléatoires : application aux mosaïques et tumeurs hétérogènes

    by Chadi Saad

    L'arrivée des technologies de séquençage d’ADN à haut-débit a représenté une révolution dans le domaine de la génomique personnalisée, en raison de leur résolution et leur faible coût. Toutefois, ces nouvelles technologies présentent un taux d’erreur élevé, qui varie entre 0,1% et 1% pour les séquenceurs de seconde génération. Cette valeur est problématique dans le cadre de la recherche de variants de faible ratio allélique, comme ce qui est observé dans le cas des tumeurs hétérogènes. En effet, un tel taux d’erreur peut mener à des milliers de faux positifs. Chaque région de l’ADN étudié doit donc être séquencée plusieurs fois, et les variants sont alors filtrés en fonction de critères basés sur leur profondeur. Malgré ces filtres, le nombre d’artefacts reste important, montrant la limite des approches conventionnelles et indiquant que certains artefacts de séquençage ne sont pas aléatoires.Dans le cadre de cette thèse, nous avons développé un algorithme exact de recherche des motifs d’ADN dégénérés sur-représentés en amont des erreurs de séquençage non aléatoires et donc potentiellement liés à leur apparition. Cet algorithme a été mis en oeuvre dans un logiciel appelé DiNAMO, qui a été testé sur des données de séquençage issues des technologies IonTorrent et Illumina.Les résultats expérimentaux ont mis en évidence plusieurs motifs, spécifiques à chacune de ces deux technologies. Nous avons ensuite montré que la prise en compte de ces motifs dans l’analyse, réduisait considérablement le taux de faux positifs. DiNAMO peut donc être utilisé en aval de chaque analyse, comme un filtre supplémentaire permettant d’améliorer l’identification des variants, en particulier des variants à faible ratio allélique.

  • Open Access

    Genome Sequencing Identifies 13 Novel Candidate Risk Genes for Autism Spectrum Disorder in a Qatari Cohort

    by Afif Ben-Mahmoud, Vijay Gupta, Alice Abdelaleem, Richard Thompson, Abdi Aden, Hamdi Mbarek, Chadi Saad, Mohamed Tolefat, Fouad Alshaban, Lawrence W. Stanton, et al.

    Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by deficits in social communication, restricted interests, and repetitive behaviors. Despite considerable research efforts, the genetic complexity of ASD remains poorly understood, complicating diagnosis and treatment, especially in the Arab population, with its genetic diversity linked to migration, tribal structures, and high consanguinity. To address the scarcity of ASD genetic data in the Middle East, we conducted genome sequencing (GS) on 50 ASD subjects and their unaffected parents. Our analysis revealed 37 single-nucleotide variants from 36 candidate genes and over 200 CGG repeats in the FMR1 gene in one subject. The identified variants were classified as uncertain, likely pathogenic, or pathogenic based on in-silico algorithms and ACMG criteria. Notably, 52% of the identified variants were homozygous, indicating a recessive genetic architecture to ASD in this population. This finding underscores the significant impact of high consanguinity within the Qatari population, which could be utilized in genetic counseling/screening program in Qatar. We also discovered single nucleotide variants in 13 novel genes not previously associated with ASD: ARSF, BAHD1, CHST7, CUL2, FRMPD3, KCNC4, LFNG, RGS4, RNF133, SCRN2, SLC12A8, USP24, and ZNF746. Our investigation categorized the candidate genes into seven groups, highlighting their roles in cognitive development, including the ubiquitin pathway, transcription factors, solute carriers, kinases, glutamate receptors, chromatin remodelers, and ion channels.


  • Open Access

    Analysis of 14,392 whole genomes reveals 3.5% of Qataris carry medically actionable variants

    by Amal Elfatih, Chadi Saad, Borbala Mifsud, Hamdi Mbarek

    Arabic populations are underrepresented in large genome projects; therefore, the frequency of clinically actionable variants among Arabs is largely unknown. Here, we investigated genetic variation in 14,392 whole genomes from the Qatar Genome Program (QGP) across the list of 78 actionable genes (v3.1) determined by the American College of Medical Genetics and Genomics (ACMG). Variants were categorized into one of the following groups: (1) Pathogenic (P), (2) Likely pathogenic (LP), and (3) Rare variants of uncertain significance with evidence of pathogenicity. For the classification, we used variant databases, effect predictors, and the disease-relevant phenotypes available for the cohort. Data on cardiovascular disease, cancer, and hypercholesterolemia allowed us to assess the disease-relevant phenotype association of rare missense variants. We identified 248 distinct variants in 50 ACMG genes that fulfilled our criteria to be included in one of the three groups affecting 1036 genotype-positive participants of the QGP cohort. The most frequent variants were in TTN, followed by RYR1 and ATP7B. The prevalence of reportable secondary findings was 3.5%. A further 46 heterozygous variants in six genes with an autosomal recessive mode of inheritance were detected in 200 individuals, accounting for an additional 1.4%. Altogether, they affect 5% of the population. Due to the high consanguinity rate in the QGP cohort (28% in spouses and 60% in parents), P and LP variants both in genes with dominant and recessive inheritance are important for developing better treatment options and preventive strategies in Qatar and the Arabic population of the Middle East.


  • Open Access

    Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative

    by Guillaume Butler-Laporte, Gundula Povysil, Jack A. Kosmicki, Elizabeth T. Cirulli, Theodore Drivas, Simone Furini, Chadi Saad, Axel Schmidt, Pawel Olszewski, Urszula Korotko, et al.

    Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.


  • Open Access

    Qatar genome: Insights on genomics from the Middle East

    by Hamdi Mbarek, Geethanjali Devadoss Gandhi, Senthil Selvaraj, Wadha Al‐Muftah, Radja Badji, Yasser Al‐Sarraj, Chadi Saad, Dima Darwish, Muhammad Alvi, Tasnim Fadl, et al.

    Despite recent biomedical breakthroughs and large genomic studies growing momentum, the Middle Eastern population, home to over 400 million people, is under-represented in the human genome variation databases. Here we describe insights from phase 1 of the Qatar Genome Program with whole genome sequenced 6,047 individuals from Qatar. We identified more than 88 million variants of which 24 million are novel and 23 million are singletons. Consistent with the high consanguinity and founder effects in the region, we found that several rare deleterious variants were more common in the Qatari population while others seem to provide protection against diseases and have shaped the genetic architecture of adaptive phenotypes. These results highlight the value of our data as a resource to advance genetic studies in the Arab and neighbouring Middle Eastern populations and will significantly boost the current efforts to improve our understanding of global patterns of human variations, human history and genetic contributions to health and diseases in diverse populations.


  • Open Access

    Poking COVID-19: Insights on Genomic Constraints among Immune-Related Genes between Qatari and Italian Populations

    by Hamdi Mbarek, Massimiliano Cocca, Yasser Al-Sarraj, Chadi Saad, Massimo Mezzavilla, Wadha AlMuftah, Dario Cocciadiferro, Antonio Novelli, Isabella Quinti, Azza AlTawashi, et al.

    Host genomic information, specifically genomic variations, may characterize susceptibility to disease and identify people with a higher risk of harm, leading to better targeting of care and vaccination. Italy was the epicentre for the spread of COVID-19 in Europe, the first country to go into a national lockdown and has one of the highest COVID-19 associated mortality rates. Qatar, on the other hand has a very low mortality rate. In this study, we compared whole-genome sequencing data of 14398 adults and Qatari-national to 925 Italian individuals. We also included in the comparison whole-exome sequence data from 189 Italian laboratory-confirmed COVID-19 cases. We focused our study on a curated list of 3619 candidate genes involved in innate immunity and host-pathogen interaction. Two population-gene metric scores, the Delta Singleton-Cohort variant score (DSC) and Sum Singleton-Cohort variant score (SSC), were applied to estimate the presence of selective constraints in the Qatari population and in the Italian cohorts. Results based on DSC and SSC metrics demonstrated a different selective pressure on three genes (MUC5AC, ABCA7, FLNA) between Qatari and Italian populations. This study highlighted the genetic differences between Qatari and Italian populations and identified a subset of genes involved in innate immunity and host-pathogen interaction.


  • Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19

    by Gundula Povysil, Guillaume Butler-Laporte, Ning Shang, Chen Wang, Atlas Khan, Manal Alaamery, Tomoko Nakanishi, Sirui Zhou, Vincenzo Forgetta, Robert J.M. Eveleigh, et al.

    A recent report found that rare predicted loss-of-function (pLOF) variants across 13 candidate genes in TLR3- and IRF7-dependent type I IFN pathways explain up to 3.5% of severe COVID-19 cases. We performed whole-exome or whole-genome sequencing of 1,864 COVID-19 cases (713 with severe and 1,151 with mild disease) and 15,033 ancestry-matched population controls across 4 independent COVID-19 biobanks. We tested whether rare pLOF variants in these 13 genes were associated with severe COVID-19. We identified only 1 rare pLOF mutation across these genes among 713 cases with severe COVID-19 and observed no enrichment of pLOFs in severe cases compared to population controls or mild COVID-19 cases. We found no evidence of association of rare LOF variants in the 13 candidate genes with severe COVID-19 outcomes.


  • Open Access

    DiNAMO: highly sensitive DNA motif discovery in high-throughput sequencing data

    by Chadi Saad, Laurent Noé, Hugues Richard, Julie Leclerc, Marie-Pierre Buisine, Hélène Touzet, Martin Figeac

    Discovering over-represented approximate motifs in DNA sequences is an essential part of bioinformatics. This topic has been studied extensively because of the increasing number of potential applications. However, it remains a difficult challenge, especially with the huge quantity of data generated by high throughput sequencing technologies. To overcome this problem, existing tools use greedy algorithms and probabilistic approaches to find motifs in reasonable time. Nevertheless these approaches lack sensitivity and have difficulties coping with rare and subtle motifs. We developed DiNAMO (for DNA MOtif), a new software based on an exhaustive and efficient algorithm for IUPAC motif discovery. We evaluated DiNAMO on synthetic and real datasets with two different applications, namely ChIP-seq peaks and Systematic Sequencing Error analysis. DiNAMO proves to compare favorably with other existing methods and is robust to noise. We shown that DiNAMO software can serve as a tool to search for degenerate motifs in an exact manner using IUPAC models. DiNAMO can be used in scanning mode with sliding windows or in fixed position mode, which makes it suitable for numerous potential applications. https://github.com/bonsai-team/DiNAMO .


  • Open Access

    Improving bioinformatics prediction of microRNA targets by ranks aggregation

    by Aurélien Quillet, Chadi Saad, Gaētan Ferry, Youssef Anouar, Nicolas Vergne, Thierry Lecroq, Christophe Dubessy

    MicroRNAs are non-coding RNAs which down-regulate a large number of target mRNAs and modulate cell activity. Despite continued progress, bioinformatics prediction of microRNA targets remains a challenge since available softwares still suffer from a lack of accuracy and sensitivity. Moreover, these tools show fairly inconsistent results from one another. Thus, in an attempt to circumvent these difficulties, we aggregated all human results of three important prediction algorithms (miRanda, PITA and SVmicrO) showing additional characteristics in order to rerank them into a single list. This database is freely available through a webtool called miRabel ( http://bioinfo.univ-rouen.fr/mirabel/ ) which can take either a list of miRNAs, genes or signaling pathways as search inputs. Receiver Operating Characteristic curves and Precision-Recall curves analysis carried out using experimentally validated data and very large datasets show that miRabel significantly improves the prediction of miRNA targets compared to the three algorithms used separatly. Moreover, using the same analytical methods, miRabel shows significantly better predictions than other popular algorithms such as MBSTAR and miRWalk. Interestingly, a F-score analysis revealed that miRabel also significantly improves the relevance of the top results. The aggregation of results from different databases is therefore a powerful and generalizable approach to many other species to improve miRNA target predictions. Thus, miRabel is an efficient tool to accurately identify miRNA targets and integrate them into a biological context.